TGF-β inducible early gene 1 regulates osteoclast differentiation and survival by mediating the NFATc1, AKT, and MEK/ERK signaling pathways

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Cicek, Muzaffer ^a   Vrabel, Anne ^b   Sturchio, Catherine ^b   Pederson, Larry ^b   Hawse, John R ^a   Subramaniam, Malayannan ^a   Spelsberg, Thomas C ^a   Oursler, Merry Jo ^a,b  

^a MAYO GRADUATE SCHOOL   (United States)

^b Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN KINASE B; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NFATC1; TRANSFORMING GROWTH FACTOR BETA INDUCIBLE EARLY GENE 1; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NFATC1 PROTEIN, MOUSE; TIEG1 PROTEIN, MOUSE; TRANSCRIPTION FACTOR NFAT; TRANSFORMING GROWTH FACTOR BETA1;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DC STAMP GENE; DRUG ACTIVITY; ENZYME ACTIVATION; GENE; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PHENOTYPE; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BIOLOGICAL MODEL; CELL DIFFERENTIATION; CYTOLOGY; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; PHOSPHORYLATION; STEM CELL;

MUS;

ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL SURVIVAL; DNA-BINDING PROTEINS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MODELS, BIOLOGICAL; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RANK LIGAND; STEM CELLS; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79952642781     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017522     Document Type: Article

References (47)

1. Jimi E, Aoki K, Saito H, D'Acquisto F, May MJ, et al. (2004) Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 10: 617-624.
2. Michigami T, Ihara-Watanabe M, Yamazaki M, Ozono K, (2001) Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res 61: 1637-1644.
3. Mansky KC, Sankar U, Han J, Ostrowski MC, (2002) Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-kappa B ligand signaling. J Biol Chem 277: 11077-11083.
4. Ikeda F, Matsubara T, Tsurukai T, Hata K, Nishimura R, et al. (2008) JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts. J Bone Miner Res 23: 907-914.
5. Gingery A, Bradley E, Shaw A, Oursler MJ, (2003) Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NFkappaB pathways to maintain osteoclast survival. J Cell Biochem 89: 165-179.
6. Sugatani T, Hruska KA, (2005) Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. J Biol Chem 280: 3583-3589.
7. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, et al. (2002) RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 416: 744-749.
8. Kawaguchi N, Noda M, (2000) Mitf is expressed in osteoclast progenitors in vitro. Exp Cell Res 260: 284-291.
9. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, et al. (2002) Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3: 889-901.
10. Yagi M, Miyamoto T, Sawatani Y, Iwamoto K, Hosogane N, et al. (2005) DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 202: 345-351.
11. Miyamoto T, (2006) The dendritic cell-specific transmembrane protein DC-STAMP is essential for osteoclast fusion and osteoclast bone-resorbing activity. Mod Rheumatol 16: 341-342.
12. Kim K, Lee SH, Ha Kim J, Choi Y, Kim N, (2008) NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol Endocrinol 22: 176-185.
13. Oursler M, (2010) Recent Advances In Understanding The Mechanisms Of Osteoclast Precursor Fusion. Journal of Cellular Biochemistry (in press).
14. Subramaniam M, Harris SA, Oursler MJ, Rasmussen K, Riggs BL, et al. (1995) Identification of a novel TGF-beta-regulated gene encoding a putative zinc finger protein in human osteoblasts. Nucleic Acids Res 23: 4907-4912.
15. Blok LJ, Grossmann ME, Perry JE, Tindall DJ, (1995) Characterization of an early growth response gene, which encodes a zinc finger transcription factor, potentially involved in cell cycle regulation. Mol Endocrinol 9: 1610-1620.
16. Chalaux E, Lopez-Rovira T, Rosa JL, Pons G, Boxer LM, et al. (1999) A zinc-finger transcription factor induced by TGF-beta promotes apoptotic cell death in epithelial Mv1Lu cells. FEBS Lett 457: 478-482.
17. Ribeiro A, Bronk SF, Roberts PJ, Urrutia R, Gores GJ, (1999) The transforming growth factor beta(1)-inducible transcription factor TIEG1, mediates apoptosis through oxidative stress. Hepatology 30: 1490-1497.
18. Tachibana I, Imoto M, Adjei PN, Gores GJ, Subramaniam M, et al. (1997) Overexpression of the TGFbeta-regulated zinc finger encoding gene, TIEG, induces apoptosis in pancreatic epithelial cells. J Clin Invest 99: 2365-2374.
19. Tau KR, Hefferan TE, Waters KM, Robinson JA, Subramaniam M, et al. (1998) Estrogen regulation of a transforming growth factor-beta inducible early gene that inhibits deoxyribonucleic acid synthesis in human osteoblasts. Endocrinology 139: 1346-1353.
20. Cook T, Gebelein B, Belal M, Mesa K, Urrutia R, (1999) Three conserved transcriptional repressor domains are a defining feature of the TIEG subfamily of Sp1-like zinc finger proteins. J Biol Chem 274: 29500-29504.
21. Liu C, Calogero A, Ragona G, Adamson E, Mercola D, (1996) EGR-1, the reluctant suppression factor: EGR-1 is known to function in the regulation of growth, differentiation, and also has significant tumor suppressor activity and a mechanism involving the induction of TGF-beta1 is postulated to account for this suppressor activity. Crit Rev Oncog 7: 101-125.
22. Zhang JS, Moncrieffe MC, Kaczynski J, Ellenrieder V, Prendergast FG, et al. (2001) A conserved alpha-helical motif mediates the interaction of Sp1-like transcriptional repressors with the corepressor mSin3A. Mol Cell Biol 21: 5041-5049.
23. Bensamoun SF, Hawse JR, Subramaniam M, Ilharreborde B, Bassillais A, et al. (2006) TGFbeta inducible early gene-1 knockout mice display defects in bone strength and microarchitecture. Bone 39: 1244-1251.
24. Hawse JR, Iwaniec UT, Bensamoun SF, Monroe DG, Peters KD, et al. (2008) TIEG-null mice display an osteopenic gender-specific phenotype. Bone 42: 1025-1031.
25. Subramaniam M, Gorny G, Johnsen SA, Monroe DG, Evans GL, et al. (2005) TIEG1 null mouse-derived osteoblasts are defective in mineralization and in support of osteoclast differentiation in vitro. Mol Cell Biol 25: 1191-1199.
26. Subramaniam M, Hawse JR, Bruinsma ES, Grygo SB, Cicek M, et al. TGFbeta inducible early gene-1 directly binds to, and represses, the OPG promoter in osteoblasts. Biochem Biophys Res Commun 392: 72-76.
27. Bradley EW, Ruan MM, Oursler MJ, (2008) Novel pro-survival functions of the Kruppel-like transcription factor Egr2 in promotion of macrophage colony-stimulating factor-mediated osteoclast survival downstream of the MEK/ERK pathway. J Biol Chem 283: 8055-8064.
28. Jiang L, Chen Y, Chan CY, Wang X, Lin L, et al. (2009) Down-regulation of stathmin is required for TGF-beta inducible early gene 1 induced growth inhibition of pancreatic cancer cells. Cancer Lett 274: 101-108.
29. Kim HH, Chung WJ, Lee SW, Chung PJ, You JW, et al. (2003) Association of sustained ERK activity with integrin beta3 induction during receptor activator of nuclear factor kappaB ligand (RANKL)-directed osteoclast differentiation. Exp Cell Res 289: 368-377.
30. Miyazaki T, Katagiri H, Kanegae Y, Takayanagi H, Sawada Y, et al. (2000) Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J Cell Biol 148: 333-342.
31. Oursler MJ, Bradley EW, Elfering SL, Giulivi C, (2005) Native, not nitrated, cytochrome c and mitochondria-derived hydrogen peroxide drive osteoclast apoptosis. Am J Physiol Cell Physiol 288: C156-168.
32. Kuroda Y, Hisatsune C, Nakamura T, Matsuo K, Mikoshiba K, (2008) Osteoblasts induce Ca2+ oscillation-independent NFATc1 activation during osteoclastogenesis. Proc Natl Acad Sci U S A 105: 8643-8648.
33. Crotti TN, Sharma SM, Fleming JD, Flannery MR, Ostrowski MC, et al. (2008) PU.1 and NFATc1 mediate osteoclastic induction of the mouse beta3 integrin promoter. J Cell Physiol 215: 636-644.
34. Kim K, Kim JH, Lee J, Jin HM, Lee SH, et al. (2005) Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis. J Biol Chem 280: 35209-35216.
35. Zhou H, Kartsogiannis V, Quinn JM, Ly C, Gange C, et al. (2002) Osteoclast inhibitory lectin, a family of new osteoclast inhibitors. J Biol Chem 277: 48808-48815.
36. Nakamura A, Ly C, Cipetic M, Sims NA, Vieusseux J, et al. (2007) Osteoclast inhibitory lectin (OCIL) inhibits osteoblast differentiation and function in vitro. Bone 40: 305-315.
37. Lee SE, Chung WJ, Kwak HB, Chung CH, Kwack KB, et al. (2001) Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK. J Biol Chem 276: 49343-49349.
38. Bradley EW, Ruan MM, Vrable A, Oursler MJ, (2008) Pathway crosstalk between Ras/Raf and PI3K in promotion of M-CSF-induced MEK/ERK-mediated osteoclast survival. J Cell Biochem 104: 1439-1451.
39. Gingery A, Bradley EW, Pederson L, Ruan M, Horwood NJ, et al. (2008) TGF-beta coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival. Exp Cell Res 314: 2725-2738.
40. Bradley EW, Ruan MM, Oursler MJ, (2008) PAK1 is a novel MEK-independent raf target controlling expression of the IAP survivin in M-CSF-mediated osteoclast survival. J Cell Physiol 217: 752-758.
41. Sutherland KA, Rogers HL, Tosh D, Rogers MJ, (2009) RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro. Arthritis Res Ther 11: R58.
42. Jaworski ZF, Duck B, Sekaly G, (1981) Kinetics of osteoclasts and their nuclei in evolving secondary Haversian systems. J Anat 133: 397-405.
43. Dvorak MM, Riccardi D, (2004) Ca2+ as an extracellular signal in bone. Cell Calcium 35: 249-255.
44. Kameda T, Mano H, Yamada Y, Takai H, Amizuka N, et al. (1998) Calcium-sensing receptor in mature osteoclasts, which are bone resorbing cells. Biochem Biophys Res Commun 245: 419-422.
45. Maeno S, Niki Y, Matsumoto H, Morioka H, Yatabe T, et al. (2005) The effect of calcium ion concentration on osteoblast viability, proliferation and differentiation in monolayer and 3D culture. Biomaterials 26: 4847-4855.
46. Mamillapalli R, VanHouten J, Zawalich W, Wysolmerski J, (2008) Switching of G-protein usage by the calcium-sensing receptor reverses its effect on parathyroid hormone-related protein secretion in normal versus malignant breast cells. J Biol Chem 283: 24435-24447.
47. Cicek M, Iwaniec UT, Goblirsch MJ, Vrabel A, Ruan M, et al. (2007) 2-Methoxyestradiol suppresses osteolytic breast cancer tumor progression in vivo. Cancer Res 67: 10106-10111.